Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06400095
Other study ID # RAMOCTANE
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 1, 2023
Est. completion date July 2024

Study information

Verified date May 2024
Source CentraCare
Contact Ramakanth Pata, MD FCCP
Phone 320-240-2207
Email cookybrey1@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a single-centre prospective observational study aimed to determine if Pocc (occlusion pressure at 100 msec), TCe ( Expiratory time constant ), Mechanical Stress power, Ventilatory ratio and C20/Cdyn would predict outcomes in patients with moderately severe ARDS (Acute respiratory distress syndrome), who are on mechanical ventilation


Description:

Severe ARDS is characterized by significant lung heterogeneity with areas of collapse, consolidation and normal lung parenchyma. Institution of mechanical ventilation may result in Ventilation-induced lung injury because of significant heterogeneity with associated volutrauma, atelectrauma and barotrauma. Underassistance results in persistent atelectasis and resultant diffusion abnormalities and over-assistance causes ventilator-associated lung injury. Mechanical power and driving pressure have been demonstrated to predict mortality in patients with Acute respiratory distress syndrome who are on mechanical ventilators. Mechanical work is the energy delivered to the respiratory system during a single inspiratory cycle and is calculated by solving the integral of airway pressure to change in volume. Mechanical power is work multiplied by RR(Respiratory rate). In the clinical setting, various equations have been used to calculate mechanical power. Mechanical Stress is defined as the internal distribution of force per unit area to an external load and associated deformation has been referred to as Strain. Stress is derived from specific lung elastance. Mechanical stress power is the power associated with internal forces required to maintain internal stresses within an object and is a part of mechanical power that is not converted to kinetic energy but rather into heat and change in internal energy. The time constant is a measure of respiratory mechanics and is calculated by the product of compliance and resistance. Theoretically, it is the time needed for the lungs to fill or be emptied at a stable pressure. The expiratory time constant can indirectly represent lung heterogeneity during passive exhalation. It has been proposed that a shorter expiratory time constant can lead to VILI and a longer time constant can lead to hyperinflation and auto-PEEP. The C20/C (Compliance 20/overall compliance) index measures the ratio of compliance of the last 20% of breath to the compliance of the entire breath. It is believed that C20/C > 1 indicates tidal recruitment and C20/C < 1 indicates overinflation. Pulmonary dead space fraction ( Vd/Vt) is an independent predictor of mortality after adjusting for PF ratio and PEEP. The ventilatory ratio has been proposed as a simplified bedside tool as a surrogate for the dead space ratio. Ventilatory Ratio (VR) is defined as minute ventilation ( ml/min) * PaCO2/Predicted body weight * 100* 37.5. For those patients, who satisfy inclusion and exclusion criteria, Day 1 will be considered as the the day of intubation. Age, gender, Charleston co-morbidity index, SOFA (Sequential organ function assessment) score at the time of intubation. For day 1 to day 3, we shall record average values of Pocc, TCe, C20/C index, Ventilatory ratio, Mechanical stress power, and PF ratio (PaO2/FiO2 ratio) will be recorded. Outcome data such as the need for vasopressors, prone position, duration of ICU stay, MAKE outcomes, need for paralysis, change in the mode of ventilator, ventilator number of days, hospital stay and 30-day outcomes including disability and survival. Statistical Analysis: Only de-identified data will be recorded on the spreadsheet. Baseline demographic features and descriptive clinical data will be summarized using means +/- SDs or medians with interquartile ranges (IQR) for continuous variables. Percentages will be used for categorical variables. For normally distributed data, t test will be used to compare the two groups. For skewed data or categorical data, a non-parametric Mann-Whitney U test and Kruskal-Wallis test will be used. For categorical data, comparisons will be made using a Pearson or chi-square or the Fisher exact test as appropriate. for more than two groups, one-way ANOVA (Analysis of variance) will be employed. The receiver operating characteristic approach will be used to identify the clinical significance of each of these variables. Univariate analysis will be performed to identify predictors of outcomes. If any factors are found significant, data will be subjected to multivariate logistic regression analysis and the corresponding adjusted odds ratio will be calculated. Pearson correlation and Bland-Altman analysis will be used as needed. For all comparisons, a p-value of < 0.05 is considered significant. Jamovi will be used for statistical analysis. Only de-identified data will be recorded on the spreadsheet


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date July 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group 19 Years to 80 Years
Eligibility Inclusion Criteria: - Patients with Acute respiratory failure needing mechanical ventilation - Diagnosis of Severe ARDS with severity: PF ratio < 150, with PEEP/CPAP > 5 Exclusion Criteria: - r2 < 0.95, monitored on the ventilator - Expiratory flow that is not first-order or non-exponential decay - Patients with Nor-epinephrine requirements > 0.1 mcg/kg/min within 2 hours of intubation - Patients requiring ECMO ( Extracorporeal membrane oxygenation) - Patients with COPD or pulmonary fibrosis with a premorbid FEV1 < 1.5 L - Severe atherosclerotic vascular disease - Patients with a chest tube, intra-abdominal hypertension or with its risk factors - Patients with structural heart disease including pulmonary hypertension (RVSP > 45) and heart failure - All comfort care orders in the ICU - Patients who underwent tracheostomy

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Poccl, Time constant, driving pressure
Ventilatory parameters

Locations

Country Name City State
United States St Cloud Hospital Saint Cloud Minnesota

Sponsors (1)

Lead Sponsor Collaborator
CentraCare

Country where clinical trial is conducted

United States, 

References & Publications (2)

Guttmann J, Eberhard L, Fabry B, Bertschmann W, Zeravik J, Adolph M, Eckart J, Wolff G. Time constant/volume relationship of passive expiration in mechanically ventilated ARDS patients. Eur Respir J. 1995 Jan;8(1):114-20. doi: 10.1183/09031936.95.08010114. — View Citation

Paudel R, Trinkle CA, Waters CM, Robinson LE, Cassity E, Sturgill JL, Broaddus R, Morris PE. Mechanical Power: A New Concept in Mechanical Ventilation. Am J Med Sci. 2021 Dec;362(6):537-545. doi: 10.1016/j.amjms.2021.09.004. Epub 2021 Sep 28. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Survival or mortality We will assess whether the patient would survive or not From the date of enrollment to 90 days from enrolment or date of death, whichever came first, assessed up to 90 days.
Secondary MAKE ( Major adverse kidney events) Will assess the need for dialysis or any evidence of acute kidney injury From the date of enrollment to 90 days from enrolment or date of death, whichever came first, assessed up to 90 days.
Secondary ICU and Hospital length of stay we shall assess the duration of patients stay in the ICU and in the hospital From the date of enrollment to the number of days in ICU and in the hospital until discharge or date of death whichever came first, assessed up to 90 days
See also
  Status Clinical Trial Phase
Completed NCT04435613 - Clinical and Physiological Assessment of a Nearly Ultra-protective Lung Ventilation Strategy: A Quasi-experimental Preliminary Study in ARDS Patients N/A
Enrolling by invitation NCT05020210 - Effect of Early Treatment With Sivelestat Sodium in ARDS Patients
Completed NCT04468971 - REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia Phase 1
Completed NCT04505592 - Tenecteplase in Patients With COVID-19 Phase 2
Completed NCT04493242 - Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS Phase 2
Withdrawn NCT04909879 - Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome Phase 2
Completed NCT02265198 - Relationship of Pulmonary Contusion to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome N/A
Completed NCT01949272 - Optimization of PEEP for Alveolar Recruitment in ARDS N/A
Not yet recruiting NCT01668368 - Goal Directed Mechanical Ventilation Aimed at Optimal Lung Compliance N/A
Completed NCT01881061 - Lung Sonography in Patients With Acute Respiratory Distress Syndrome in Intensive Care Unit N/A
Completed NCT00808691 - Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit N/A
Completed NCT05035589 - The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
Recruiting NCT04764032 - Right Ventricular Dysfunction in Ventilated Patients With COVID-19
Completed NCT04556513 - Functional Recovery From Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19: Influence of Socio-Economic Status
Recruiting NCT06036056 - NMR Based Metabolomics Kinetics in ARDS Patients
Recruiting NCT04503876 - Effects of End-expiratory Positive Pressure Optimization in Intubated Patients With Healthy Lung or Acute Respiratory Distress Syndrome N/A
Recruiting NCT04643691 - Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS Phase 2
Completed NCT04395911 - Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections N/A
Not yet recruiting NCT05341687 - Prognostic Value of Respiratory System Compliance Under VV-ECMO on 180-day Mortality in COVID-19 ARDS.
Recruiting NCT05056090 - Effect of Prone Positioning on Mortality in Patients With Mild to Moderate Acute Respiratory Distress Syndrome. N/A